• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    FDA slams Merz over `misleading` Instagram ad for Botox rival

    FIERCE PHARMA

    Merz And World Stroke Organization Launch Stroke Care Initiative

    BUSINESSWIRE

    Merz Therapeutics Plans US Workforce Growth After $185M Asset Purchase

    FIERCE PHARMA

    Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

    BUSINESSWIRE

    Genzyme `s Biologic Xeomin (incobotulinumtoxinA) Receives Suppl Approvals in US

    FDA

    XEOMIN Receives New Therapeutic Indication In Switzerland

    BUSINESSWIRE

    Acorda files for bankruptcy, inks $185M asset deal to Merz

    FIERCE PHARMA

    XEOMIN receives three new therapeutic indications in Australia

    BUSINESSWIRE

    Merz Therapeutics Hosts Over 300 International Healthcare Professionals

    BUSINESSWIRE

    Merz`s Biologic Xeomin (incobotulinumtoxinA) Receives Approval in the U.S.

    FDA

    Allergan & Merz settle more Alzheimer`s drug pay-for-delay allegations for $54M

    ENDPTS

    XEOMIN® Receives European Approval for the Treatment of Chronic Sialorrhea

    BUSINESSWIRE

    Teijin Receives Additional Approval in Japan for Merz`s Xeomin® Botulinum Toxin

    BUSINESSWIRE

    Winhealth & Merz Collaborate on Hepa-Merz® to benefit liver patients in China

    PRNEWSWIRE

    Merz’ s Biolog Xeomin (incobotulinumtoxinA) Receive Supplemental Approval in US

    FDA

    As aesthetics procedures skyrocket post-lockdown

    FIERCE PHARMA

    Merz signs actress and lifestyle maven Paltrow as new face of injection Xeomin

    FIERCE PHARMA

    Merz splits into 3 businesses for better customer focus

    FIERCE PHARMA

    Merz Aesthetics introduces Ultherapy treatment to India

    PHARMABIZ

    Merz companies invest €50M in expansions at Dessau sites

    FIERCE PHARMA

    CUVPOSA® (glycopyrrolate) : Merz Pharms vs. Taro Pharma

    PATENT LITIGATION

    Medytox files BLA of botulinum toxin

    BIOSPECTRUM

    Merz Pharms’ Biolog Xeomin (incobotulinumtoxinA) Receive Supplemental Approval in US

    FDA

    Valeant Appoints William D. Humphries As EVP, Dermatology

    PR NEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.